Effect of letrozole and raloxifene on in vitro human endometrial stromal cells

Document Type : Original Article

Authors

1 PhD of Histology, Department of Anatomical Sciences, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

2 Assistant Professor, PhD of Reproductive Biology, Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

3 Professor, PhD of Anatomical Sciences, Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Abstract

Introduction: Letrozole and raloxifene are used in female reproductive disease. They have special properties and side-effects. This study was performed with aim to compare the in vitro effects of letrozole and raloxifene on human endometrial stromal cells.
Methods: This experimental study was performed in 2019 on 16 samples of endometrial biopsy of women with normal menstrual cycles in secretory phase. Endometrial biopsies were digested by collagenase type I. Stromal cells were harvested by using serial filtration of cell suspension through cell strainer (70 and 40 µm) and ficoll layering. The cells were confirmed by immunohistochemical staining for vimentin. The cells of each biopsy were divided into: control and letrozole, or control and raloxifene. After 15 day, morphological changes and cell viability were determined. Data were analyzed by one way ANOVA and Tukey test.
Results: Cell viability in control and letrozole 0.1, 1 and 10 µM concentration was 14.7, 7.8, 5.6 and 4.2 ×104 cells, respectively. Cell viability in control and raloxifene 0.1, 1 and 10 µM was 21.8, 12.9, 9.1 and 3×104 cells, respectively; the difference was significant (P<0.05). The morphological changes score of cells were 3.86, 3.38, 2.68 and 2.08 in control and letrozole groups, and were 3.98, 3.77, 3.72, 1.18 in control and raloxifene; the difference was significant (P<0.05). The effect of letrozole and raloxifene on the bioavailability and morphology of endometrial stromal cells was different.
Conclusion: Letrozole and raloxifene showed anti-proliferative and dose-dependent effects on in vitro human endometrial stromal cells and raloxifene effect was more potent than letrozole.

Keywords

References

  1. Carlson BM. Human Embryology and Developmental Biology E-Book: Elsevier Health Sciences; 2018.
  2. Arnold JT, Kaufman DG, Seppala M, Lessey BA. Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Human reproduction 2001; 16(5):836-45.
  3. Danforth DN. Danforth's obstetrics and gynecology: Lippincott Williams & Wilkins; 2008.
  4. Talebi Tamajani Z, Mohammadi SD, Gorji M, Alimoradi Z. Comparison of the efficacy of Letrozole versus Clomiphene Citrate among Iranian infertile females: A systematic review and meta-analysis. The Iranian Journal of Obstetrics, Gynecology and Infertility 2019; 22(7):89-102.
  5. Haynes B, Dowsett M, Miller W, Dixon J, Bhatnagar A. The pharmacology of letrozole. The Journal of steroid biochemistry and molecular biology 2003; 87(1):35-45.
  6. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertility and sterility 2004; 81(2):290-6.
  7. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertility and sterility 2001; 75(2):305-9.
  8. Scott J, Da CC, Early J. Raloxifene: a selective estrogen receptor modulator. American family physician 1999; 60(4):1131-9.
  9. Lam PM, Yim SF, Briton-Jones C, Chung TKH, Haines C. Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor. Fertility and sterility 2004; 81(2):393-7.
  10. Kalidas M, Hilsenbeck S, Brown P. Defining the role of raloxifene for the prevention of breast cancer. Oxford University Press; 2004.
  11. Palomba S, Orio Jr F, Morelli M, Russo T, Pellicano M, Zupi E, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. The Journal of Clinical Endocrinology & Metabolism 2002; 87(8):3603-8.
  12. Jeong EJ, Liu Y, Lin H, Hu M. Species-and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug metabolism and disposition 2005; 33(6):785-94.
  13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281(23):2189-97.
  14. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer. Molecular medicine reports 2015; 11(3):1566-72.
  15. Bläuer M, Heinonen PK, Rovio P, Ylikomi T. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model. Eur J Pharmacol 2008; 592(1-3):13-8.
  16. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15(3):342-55.
  17. Yanaihara A, Otsuka Y, Iwasaki S, Aida T, Tachikawa T, Irie T, et al. Differences in gene expression in the proliferative human endometrium. Fertil Steril 2005; 83(4):1206-15.
  18. Khazaei M, Roshankhah S, Ghorbani R, Chobsaz F. Sildenafil effect on nitric oxide secretion by normal human endometrial epithelial cells cultured in vitro. Int J Fertil Steril 2011; 5(3):142-7.
  19. Esfandiari N, Khazaei M, Ai J, Nazemian Z, Jolly A, Casper RF. Angiogenesis following three-dimensional culture of isolated human endometrial stromal cells. Int J Fertil Steril 2008; 2(1):19-22.
  20. TW S. Langman’s Medical Embryology. Lippincott Williams & Wilkins. Philadelphia Pennsylvania USA; 2011.
  21. Pole J, Carmichael P, Griffin J. Identification of transcriptional biomarkers induced by SERMS in human endometrial cells using multivariate analysis of DNA microarrays. Biomarkers 2004; 9(6):447-60.
  22. Guan YM, Carlberg M, Bruse C, Carlstrom K, Bergqvist A. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells. Acta Obstet Gynecol Scand 2002; 81(5):389-97.
  23. Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L Jr, Shah A, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999; 6(3):188-95.
  24. DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 2008; 26(25):4151-9.
  25. Mostafa Gharabaghi P, Azadi A, Dastranj Tabrizi A, Ouladsahebmadarek E, Tasbihi P, Shoari N. Effect of letrozole on endometrial histology in patients with disordered proliferative endometrium and simple hyperplasia. Int J Women’s Health Reproduction Sci 2014; 2(2):73-79.
  26. Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009; 25(5):1105-9.
  27. Selim MF, Borg TF. Letrozole and clomiphene citrate effect on endometrial and subendometrial vascularity in treating infertility in women with polycystic ovary syndrome. Journal of Gynecologic Surgery 2012; 28(6):405-10..
  28. Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecologic oncology. 2001;82(2):384-8.
  29. Khazaei M, Montaseri A, Casper RF. Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix. Fertil Steril 2009; 91(5 Suppl):2172-6.
  30. Fang Z, Yang S, Gurates B, Tamura M, Simpson E, Evans D, et al. Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue. J Clin Endocrinol Metab 2002; 87(7):3460-6.
  31. Meresman GF, Bilotas M, Abello V, Buquet R, Tesone M, Sueldo C. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005; 84(2):459-63.
  32. Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol 2006; 103(2):599-603.
  33. Kijima I, Itoh T, Chen S. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. J Steroid Biochem Mol Biol 2005; 97(4):360-8.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 23, Issue 5
July 2020
Pages 26-34

Files

Share

How to cite

Statistics